The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.
 
Nicholas Mai
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - IntegrityCE
Travel, Accommodations, Expenses - MJH Life Sciences
 
Anton Safonov
No Relationships to Disclose
 
Antonio Marra
Consulting or Advisory Role - Menarini Group
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Yuan Chen
No Relationships to Disclose
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
George Plitas
Consulting or Advisory Role - Merck; PAIGE.AI; Takeda; Tizona Therapeutics, Inc.; Trishula Therapeutics
Speakers' Bureau - Merck
Research Funding - Takeda
Patents, Royalties, Other Intellectual Property - Anti-CCR8 agents